
ANTX Stock Forecast & Price Target
ANTX Analyst Ratings
Bulls say
AN2 Therapeutics Inc. has demonstrated promising results from its Phase 2 trials of epetraborole, which has shown good safety and tolerability, as well as potential benefits for quality of life in patients with non-tuberculous mycobacterial (NTM) infections. The positive impact on cough frequency and intensity, coupled with strong pre-clinical data supporting its efficacy for treating more challenging forms of NTM, positions epetraborole as a potentially significant development in the therapeutic landscape. Overall, the company's commitment to advancing its boron-based compounds for various infectious diseases and oncology, alongside encouraging clinical outcomes, bolsters a positive long-term outlook for its stock.
Bears say
AN2 Therapeutics Inc faces significant challenges, highlighted by poor clinical trial results for its lead candidate, epetraborole, which raises concerns about the efficacy and safety of its drug pipeline. The company has a history of financial losses and lacks a track record of profitability, suggesting it may struggle to secure favorable partnerships or successfully commercialize its products. Moreover, potential litigation and regulatory risks further complicate AN2's ability to protect its market exclusivity and effectively navigate competitive pressures, painting a bleak outlook for its future.
This aggregate rating is based on analysts' research of AN2 Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ANTX Analyst Forecast & Price Prediction
Start investing in ANTX
Order type
Buy in
Order amount
Est. shares
0 shares